Conclusions
NT-proBNP is an independent predictor of malignancies in the short-term
in patients with stable CAD. If these findings are confirmed in further
studies, this biomarker could be helpful in assessing the global
prognosis in patients with CAD.
Acknowledgements: Oliver Shaw (QuirĂ³n, Spain) assisted us in
editing this work.
Funding: This work was supported by grants from Fondo de
Investigaciones Sanitarias [PI05/0451, PI14/1567, PI17/01615];
Spanish Society of Cardiology; Spanish Society of Arteriosclerosis.
RECAVA [RD06/0014/0035]; Instituto de Salud Carlos III FEDER [FJD
biobank: RD09/0076/00101].